BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 17, 2024
See today's BioWorld
Home
» Phase II clinical trials: March 2020
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Phase II clinical trials: March 2020
April 10, 2020
No Comments
Therapeutic area data reported by biopharma companies on phase II trials in March 2020, including: Acceleron, Akero, Albireo, Algernon, Allakos, Axsome, Can-Fite, Cellphire, Chugai, Cortexyme, Cytodyn, Delmar, Diffusion, Engage, Genfit, Hansa, Horizon, Ideaya, Immutep, Innovent, Inovio, Irlab, ISA, Leading, Matinas, Mediwound, Moderna, Nantkwest, Neuraly, Obseva, Oncolys, Oncoquest, Opthea, Orchard, Orphomed, Orthotrophix, Ovid, Palvella, Phasebio, Proqr, Qurient, Redhill, Regeneron, Revive, Sanofi, Santen, Seres, Synlogic, Tenax, Theralase, Theranexus, Tracon, Uniqure, Vaccitech, Vivoryon, Xenon, Zealand.
BioWorld
Analysis and data insight